Clinical Trial of Autologous Adipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence

Inclusion Criteria: * Males with stress urinary incontinence with insufficient effect by behavioral therapy or pharmacotherapy persisting more than 1 year after either of the following surgical procedure: * Patients with symptoms after radical prostatectomy for localized prostate cancer and currently without relapse/metastasis, and PSA level less than 0.1 ng/mL for over 1 year * Patients with symptoms after transurethral prostatectomy or laser prostatectomy for prostatic hyperplasia, and PSA level less than 4.0 ng/mL over 1 year * Age of 20 or above * Mild to moderate urinary incontinence on the 24-hour pad test * Patients who can keep a bladder diary in a satisfactory manner * Patients who are willing and able to give signed consent Exclusion Criteria: * \- Concurrent with any other types of urinary incontinence * History of urinary or reproductive surgery within 6 months * History of behavioral therapy or pharmacotherapy within 3 months * Concurrent with diabetes insipidus * History of radiotherapy in the lower urinary tract * History of ADRCs treatment for stress urinary incontinence * History of any type of cell therapy within 6 months * Participation in any other clinical trial within 3 months * Concurrent with lower urinary tract obstruction * Concurrent with urolithiasis, urinary tract infection or interstitial cystitis * History of recurrent urinary tract infection * History of malignant neoplasm within 5 years or a suspicion of it * Life expectancy of less than 1 year * Any other patients whom the trial investigator deemed ineligible to this study